Cannabis and Hemp in Minnesota: A Practitioner’s Analysis of the 2026 Omnibus

Market Architecture, Hemp Integration, and the Structural Changes Operators Need to Understand

Susan Burns, JD, LL.M.

S Burns Legal PLLC | Top 200 Global Cannabis Lawyer | May 2026

Minnesota’s 2026 Cannabis Omnibus does not simply amend the rules — it sets the architecture of a market. Who enters, when, and under what conditions is now a matter of statute. The Omnibus amends chapter 342 across more than 115 sections, touching every corner of the state’s cannabis and hemp market: it creates a new top-tier cannabis license, opens the medical cannabis market to operators beyond the two existing license holders, creates a new co-location pathway for individuals who hold majority ownership in both hemp and cannabis businesses, opens a hemp hospitality pathway that had been taken away, and formally dissolves the regulatory framework under which Minnesota’s hemp market was first built.

The bill’s most consequential provisions are structural. Two existing medical cannabis operators will convert to the new macrobusiness license — the only fully vertically integrated cannabis businesses in the state — while new entrants wait until at least 2030. The hemp industry gains the return of a large-format dispensing format suited to hospitality service, modest additional formulation flexibility through a clarified combined cannabinoid ceiling, and for the first time, a viable on-site consumption pathway without an alcohol license. The adult-use cannabis market gets a formalized endorsement system, a new product category that bridges hemp and cannabis, and extended licensing caps that shape the competitive landscape through mid-2027.

These legislative changes arrive while the hemp industry faces an existential threat at the federal level. A provision in the federal appropriations act signed in late 2025 imposes a 0.4 milligram total THC per container threshold on hemp products, effective November 12, 2026 — a limit that industry economists project would eliminate 95 percent of the hemp-derived cannabinoid market. Four competing federal bills seek to prevent or delay that outcome. Minnesota’s legislative choices — creating a co-location pathway for hemp and cannabis businesses under common ownership, restoring a hemp hospitality framework, and creating the ratio hemp-infused cannabis product on the cannabis side — reflect a state-level policy judgment that this industry is worth protecting. Whether those choices survive federal pressure is the defining question for the market this bill is building.

A note on sources and effective dates. The Revisor of Statutes has not yet published updated Minnesota Statutes to reflect the Omnibus — the standard publication lag applies. Practitioners and operators should work from the enrolled bill text until updated compilations are available. Separately, the Office of Cannabis Management has not completed rulemaking under chapter 342. Several provisions of the Omnibus defer to OCM rule for operative limits and standards. Until those rules are promulgated, the enrolled bill text and any existing OCM guidance are the operative authority. The default effective date for provisions not otherwise specified is August 1, 2026. Most cannabis licensing structural changes take effect January 1, 2027.

Part I: Medical Cannabis — Market Architecture and the Macrobusiness

The Omnibus’s most consequential structural change is the creation of the cannabis macrobusiness license and the simultaneous opening of the medical cannabis market beyond it. These two moves are inseparable: the macrobusiness is the successor to the existing medical cannabis combination business, and the endorsement system that opens medical market access to other operators is the mechanism that gives the macrobusiness’s mandatory medical participation its meaning. Together they define the competitive architecture of Minnesota’s cannabis market for the next several years.

A. The Cannabis Macrobusiness

Minnesota’s top-tier cannabis license has arrived — and for now, only two operators will hold it.

The two existing medical cannabis combination business licenses convert to macrobusiness licenses by January 1, 2027. Before January 1, 2030, OCM may issue no more than eight macrobusiness licenses total — including the two conversions, leaving room for up to six additional licenses through the reclassification pathway. That pathway is available only to existing mezzobusiness operators who have met the two-year medical endorsement prerequisites and obtained OCM approval. A macrobusiness license issued directly to a new entrant — outside conversion or reclassification — is not available until January 1, 2030.

The market arithmetic is worth stating plainly. Two operators convert automatically. Six additional licenses may follow through reclassification — but only to existing mezzobusiness operators who have actively operated a medical cannabis cultivation endorsement for a minimum of two years. No reclassification petitioner can qualify before 2028 at the earliest given that requirement. A brand new entrant waits until 2030. Until then, the two converting operators are the only fully vertically integrated cannabis businesses in the state, with authority to cultivate, manufacture, and retail across both the adult-use and medical markets. Their structural market position is protected until at least 2030.

The Canopy Reduction and the Production Ratio Eliminated

That protected position comes with an operational constraint. The macrobusiness indoor cultivation limit is 38,000 square feet — less than half the prior statutory maximum of 90,000 square feet. Whether that reduction materially constrains the two converting operators depends on their actual current canopy, which is not public information. OCM retains authority to adjust canopy limits upward to meet market demand. Outdoor cultivation is capped at one acre. A macrobusiness must choose indoor or outdoor — the bill expressly prohibits both.

After each of the first three license renewals, OCM may authorize additional indoor canopy: 2,000 square feet after the first renewal, 2,000 after the second, and 3,000 after the third. That growth is discretionary — OCM may authorize it, not must.

One significant operational gain offsets the canopy constraint. The medical-to-adult-use production ratio that governed the prior structure is eliminated. Under prior law, operators were required to use at least two-thirds of cultivated cannabis for medical purposes. That ratio is struck. The macrobusiness may allocate production between medical and adult-use markets according to its own business judgment — subject to the mandatory medical market participation requirements that remain.

Mandatory Medical Market Participation

The macrobusiness license carries mandatory medical market engagement. A macrobusiness must hold a medical cannabis manufacturing endorsement and at least one other medical cannabis endorsement. This is not optional — failure to maintain the required endorsements or to carry and make available all high medical need products at each retail location subjects the license to suspension or revocation.

Retail operations are capped at eight locations. If operating more than five, at least three must be in OCM-identified high medical need areas. A macrobusiness must employ at least one certified medical cannabis consultant or licensed pharmacist — an unconditional employment mandate, not limited to individual patient transactions.

The two existing medical cannabis combination business license holders may begin purchasing lower-potency hemp edibles immediately, even before the January 1, 2027 conversion to macrobusiness status.

The Path In and the Social Equity Floor

The reclassification pathway from microbusiness to mezzobusiness, and from mezzobusiness to macrobusiness, is the only route to macrobusiness status for operators without an existing medical cannabis combination license. It is a long road. Medical cannabis endorsements do not become available until January 1, 2027 — the starting gun for the two-year operating clock. A mezzobusiness that obtains the required endorsements on day one and operates them for two years cannot petition for macrobusiness reclassification before January 1, 2029 at the earliest, with the reclassification process adding additional time beyond that. A microbusiness faces an even longer path — two years to reclassify to mezzobusiness, then two more years of endorsement operation before petitioning for macrobusiness status, putting the earliest realistic timeline at 2031 or later. The path to a larger license runs through active participation in the medical cannabis market — and through years of it.

At both reclassification tracks, the number of licenses approved for social equity qualified petitioners must equal or exceed the number approved for all other applicants. This is a statutory floor, not a preference. It does not merely pace non-social-equity reclassification — it conditions it on social equity participation. Where no social equity petitioners exist in a given round, the floor creates a practical freeze — OCM cannot approve non-social-equity reclassifications without violating the equal-or-greater requirement. The reclassification pathway depends on social equity participation. A denied petition carries no penalty — the operator retains its existing license and may petition again.

B. The Medical Cannabis Endorsement System

The Omnibus opens the medical cannabis market to licensed cannabis businesses beyond the two existing medical cannabis combination businesses by creating an endorsement system that any licensed cannabis business holding the underlying activity endorsement required for the specific medical endorsement sought may access. The prior blanket authorization under which a medical cannabis combination business could perform all authorized medical activities without an endorsement is struck. Going forward, medical cannabis activities require endorsements, and those endorsements are available across the licensing spectrum.

The existing medical cannabis endorsement framework is repealed effective January 1, 2027. In its place, three endorsement types are established: the medical cannabis cultivation endorsement, the medical cannabis manufacturer endorsement, and the medical cannabis retail endorsement.

The Three Medical Cannabis Endorsement Types

The medical cannabis cultivation, manufacturer, and retail endorsements are available to cultivators and micro, mezzo, and macrobusinesses that hold the appropriate non-medical endorsements. The table below summarizes eligibility, prerequisites, and key operational effects for each.

Endorsement	Eligible License Types	Prerequisite	Key Operational Effect
Medical Cannabis Cultivation	Microbusiness, Mezzobusiness, Macrobusiness, Cannabis Cultivator	Must hold cannabis cultivation endorsement	Additional canopy: +1,000 sq ft / ¼ acre (micro); +3,000 sq ft / ½ acre (mezzo); +6,000 sq ft / 1 acre (cultivator). Macrobusiness: canopy limits governed by license structure. At least 25% of cultivated flower must annually be sold to a cannabis business with a medical cannabis endorsement.
Medical Cannabis Manufacturer	Microbusiness, Mezzobusiness, Macrobusiness, Cannabis Manufacturer	Must hold extraction and concentration, hemp extraction and concentration, or creation of ADC endorsement	Must manufacture OCM-identified high medical need products. Micro- and mezzobusinesses may exceed cannabis manufacturing limits by dry weight up to 25% above OCM rule limit.
Medical Cannabis Retail	Microbusiness, Mezzobusiness, Macrobusiness, Cannabis Retailer	Must hold retail operations endorsement	Must carry all OCM high medical need products; ensure priority service for registry patients and caregivers. Additional retail locations in high medical need areas: +1 (micro), +2 (mezzo), +3 (retailer). OCM must publish high medical need product list including at minimum: pill, water-soluble multiparticulate, orally dissolvable products, and tincture.

All three endorsements are effective January 1, 2027.

Patient Access and Distribution Requirements

Distributing medical cannabis to a registry patient is not a standard retail transaction. Before distribution, an employee must confirm enrollment, verify identity, apply a patient-specific label, and provide any OCM-required information. Delivery requires a separate delivery license or endorsement — a business with a medical cannabis retail endorsement cannot simply drop product at a patient’s door.

Final approval for distribution is more selective than it may appear. A licensed pharmacist or certified medical cannabis consultant employed by the business must give final approval — but only when triggered: the patient’s first purchase of that product, a change in administration method, a cannabinoid concentration at least double the patient’s prior dosage, or the patient’s own request. Consultations may be conducted remotely by secure videoconference or telephone, provided identity can be confirmed and privacy requirements are met.

Effective the day following final enactment, medical cannabis flower and vaporized medical cannabinoid products may not be distributed, sold, or delivered to a registry patient under 21 years of age. Other delivery formats remain available for younger patients. The remaining distribution requirements take effect January 1, 2027.

A Unified Supply Chain

The endorsement system produces what practitioners and operators have anticipated since medical cannabis was legalized in Minnesota: a single operator, through a single license with appropriate endorsements, may serve both the adult-use and medical markets. The prior structure — in which the medical cannabis combination business operated as an isolated license type with blanket authorizations — is replaced by an integrated framework in which medical market participation is an endorsement layer available to any qualifying cannabis business. At this moment in time, that unified supply chain runs primarily through the two operators converting to macrobusiness status. The endorsement system builds the infrastructure for broader participation — whether that participation materializes depends on how quickly other operators build the endorsement track record the reclassification pathway requires.

Part II: Hemp — A Market Expanded and Integrated

The Omnibus makes three distinct moves on the hemp side of the market. First, it formally closes Minnesota’s pioneering standalone hemp regulatory framework — the first of its kind in the country — and completes its absorption into the unified cannabis regulatory structure of chapter 342. Second, it opens new operational pathways including what may be the first statutory hemp hospitality framework in the United States — on-site consumption authority for standalone hemp retailers without an alcohol license, paired with the restoration of a large-format dispensing vehicle suited to professional beverage service. Third, it makes a modest but useful amendment that increases the combined non-psychoactive cannabinoid ceiling, giving multi-cannabinoid product formulators a little more room to work.

A. From Hemp Law to Cannabis Law: The End of Separate Regulatory Schemes

A hemp-forward state, Minnesota was among the earliest to support an emerging hemp industry with a dedicated regulatory framework. First enacted in 2019 and substantially expanded in 2022, section 151.72 established testing requirements, labeling standards, age verification requirements, potency limits, and retailer registration obligations — a functional regulatory architecture built largely before federal guidance existed and before most states had addressed the question.

It worked. Minnesota’s hemp market developed under a framework that gave businesses clear rules, gave regulators enforcement tools, and gave consumers meaningful product standards. While licensing transitioned to chapter 342 on an earlier timeline, section 151.72 continued to govern product standards — labeling, testing, and potency requirements — through March 31, 2026. With the Omnibus, that framework is formally closed — its standards carried into chapter 342, OCM now the sole regulatory body, and the registration pathway that sustained thousands of hemp businesses replaced by the LPHE licensing system.

Previously, hemp businesses could operate by registering with OCM. That option is gone. All hemp businesses must now hold an LPHE license.

The significance extends beyond Minnesota. The state that built one of the first dedicated hemp regulatory frameworks has now formally dissolved it into a unified cannabis regulatory structure. Hemp is no longer a parallel track with its own statutory home — it is fully subsumed under the cannabis regulatory system that chapter 342 created. The transition has not been without cost. The consolidation of hemp into that framework forced hundreds of hemp businesses to close along the way — operators who could not meet the capital demands of a system designed for a cannabis market, and whose products were restricted, reformulated, or removed from shelves entirely by new NPC limits, packaging requirements, labeling mandates, and the removal of the scannable barcode accommodation. Section 151.72 served its market. Whether chapter 342 will do the same remains an open and contested question.

B. Hemp: Dual Licensing, Hospitality, and Labeling Reforms

Common Ownership: A New Pathway for Hemp and Cannabis Operators

For the first time, an individual who holds majority ownership in a hemp-licensed business may also hold majority ownership in a cannabis-licensed business — and operate both from the same location.

Prior law prohibited any person, cooperative, or business holding LPHE licenses from simultaneously holding a cannabis business license. That prohibition remains, but the Omnibus creates a new operational pathway alongside it. Those two separately licensed businesses may now operate from the same physical location. The businesses remain legally distinct: separate licenses, separate retail channels, separate compliance obligations. What changes is that common ownership now enables co-location. Hemp products move through the hemp license. Cannabis products move through the cannabis license. Joint liability attaches — a violation by one business exposes both to enforcement action.

One practical constraint: cannabis license applications are not currently open. The application window closed in March 2025 and OCM has not announced a new cycle. The co-location pathway exists — exercising it depends on OCM’s licensing calendar.

Hemp Hospitality: The Bar Pour Returns and the Alcohol License Barrier Falls

Two provisions in the Omnibus restore and expand hemp hospitality channels in Minnesota — one that was previously removed, one that is entirely new.

The bar-pour size hemp beverage container is back. The 750ml resealable, child-resistant format — available under the prior framework and lost in the 2025 transition to chapter 342 — is restored by the Omnibus, effective August 1, 2026. Hemp beverages may again be sold in this format, capped at 17 servings, with cannabinoid limits: THC at 5 milligrams per serving and combined non-psychoactive cannabinoids (“NPCs”) at 400 milligrams per container. The four permitted NPCS are cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC). Bars, restaurants, hotels, and hospitality operators finally have a practical dispensing vehicle for hemp beverages in the format required for professional beverage service.

The alcohol license barrier for on-site consumption is gone. Previously, LPHE retailers were required to hold an on-sale license under Minnesota’s alcohol statutes as a prerequisite to an on-site consumption endorsement. That requirement is gone. A standalone hemp retailer may now operate its own on-site consumption venue — serving individual hemp beverages and edibles such as gummies on premises — without an alcohol license. Individual serving containers may be opened and consumed on site. Multi-serving containers may not be sold for on-site consumption, and hemp beverages may not be mixed with alcohol. Effective the day following final enactment.

Together these two provisions open what may be the first statutory hemp hospitality framework in the United States: a channel for hemp operators to supply the hospitality market in a professional format, and a channel for hemp retailers to become hospitality venues in their own right.

LPHE Labeling: The Barcode Restored and the THC Symbol Exemption

The Omnibus restores a labeling accommodation removed last session and adds a new one. The scannable barcode is back. Cultivator information and manufacturer or concentrate information required on LPHE labels may again be provided through a scannable barcode affixed to the label, provided the barcode is accurate and active at all times. For manufacturers working with small-format packaging where label real estate is limited, this restoration is a material compliance relief.

The THC symbol exemption is new. A lower-potency hemp edible that contains only nonintoxicating cannabinoids approved by OCM and no THC is not required to include the universal THC warning symbol. A CBD-only or CBG-only product no longer carries the same warning marker as a THC-containing product. For manufacturers positioning products in wellness markets where the THC symbol creates consumer confusion or retail channel restriction, this differentiation is significant.

C. The Lower-Potency Hemp Edible Definition: One Targeted Amendment

The Omnibus makes one targeted amendment to the lower-potency hemp edible definition. The baseline qualifying criteria, the two product pathways — formulated products and minimally processed extracts — and the other cannabinoid limits are existing law carried forward. The bill clarifies and modestly increases the combined NPC ceiling.

The Amendment: A Combined NPC Ceiling

The existing definition permits up to 100 milligrams of each individual NPC — CBD, CBG, CBN, and CBC — per serving or container. The Omnibus adds a combined ceiling: any combination of the four NPCs must not exceed 400 milligrams per serving or container, and the individual amount of each must not exceed 100 milligrams. The bill also substitutes “up to” for “no more than” — a drafting clarification without substantive effect.

The combined ceiling is the operative constraint on multi-cannabinoid product formulation. A single-NPC product — CBD only, for example — is unaffected. A multi-NPC product must be formulated so that no serving exceeds 400 milligrams combined across all four NPCs regardless of the individual per-NPC limits.

The Packaging Limits

Solid non-beverage LPHE products may contain up to 1,000 milligrams per individual NPC per package — a limit carried forward from existing law, not introduced by the Omnibus. OCM rulemaking or guidance will be needed to give operators a clear and workable standard for multi-NPC product formulation.

Part III: Adult-Use Cannabis — Operational Framework

The Omnibus’s adult-use cannabis provisions are largely structural — formalizing the endorsement system, creating a new product category that bridges hemp and cannabis, extending the licensing caps that shape market entry, and establishing mandatory warning language requirements. Medical cannabis endorsements, available to qualifying cannabis businesses across license types, are addressed in Part I. What follows covers the adult-use operational framework that governs licensed cannabis businesses through 2027 and beyond.

A. The Cannabis Licensing Architecture

The Endorsement System

The Omnibus formalizes the cannabis licensing framework as an endorsement-based system. Cultivation, extraction, manufacturing, retail operations, cannabis flower packaging, and transportation between facilities each require a specific endorsement — applied for and obtained separately from the base license. Endorsements are free to apply for, aligned to the license renewal period, and subject to denial if the license holder has had a prior endorsement suspended or revoked within five years, owes outstanding fines, or does not meet the activity-specific requirements.

A New Product Category: The Ratio Hemp-Infused Cannabis Product

The Omnibus creates a new cannabis product category effective January 1, 2027: the ratio hemp-infused cannabis product. It combines cannabis-derived THC with hemp-derived NPCs in concentrations that may differ from those naturally occurring in the plant. OCM approval is required.

Potency limits: no more than 100 milligrams of NPCs per serving; for edibles, no more than 10 milligrams THC per serving and 200 milligrams THC per package; for beverages, no more than 10 milligrams THC per serving with a maximum of two servings per container; for transdermal, topical, and vaporized formats, OCM sets limits by rule.

The classification is the critical point for operators. The ratio hemp-infused cannabis product is a cannabis product — explicitly not a lower-potency hemp edible or hemp-derived consumer product. Operators building a product line in this category must hold a cannabis retail license with the appropriate endorsement. Every label must include the statement: “This product contains nonintoxicating cannabinoids derived from hemp.”

Cannabis Flower Prepackaging

The dispensary jar-and-scale model ends as the default with the Omnibus. All cannabis flower sold to customers or patients must be prepackaged unless the selling business holds a cannabis flower packaging endorsement. Operators who wish to continue weighing out flower at point of sale must apply for and obtain that endorsement, which requires a retail operations endorsement as a prerequisite.

Testing Facility Transport: A Temporary Provision

A new temporary provision allows cannabis microbusinesses, mezzobusinesses, cultivators, and manufacturers to transport product samples directly to a cannabis testing facility without holding a separate transporter license, provided they meet manifest, vehicle, and insurance requirements. Effective the day following final enactment. This provision expires February 1, 2029. Operators should ensure transporter licensing is in place before that date.

B. License Cap Dates Extended

Minnesota limits the total number of cannabis licenses it will issue — a deliberate market management tool that controls the pace of market entry. Those caps remain in place through July 1, 2027 — one year longer than originally planned. The numbers are unchanged: 25 cultivator licenses, 12 manufacturer licenses, 75 retailer licenses, and 50 mezzobusiness licenses, each split equally between social equity and general applicants.

The practical significance is forward-looking. Cannabis license applications are not currently open — only LPHE licensing is accepting applications on a rolling basis. But when cannabis licensing does reopen, OCM will not have authority to expand license counts beyond the existing caps until July 1, 2027. Operators and investors planning market entry should factor that constraint into their timelines.

C. Mandatory Warning Language

The Omnibus expands warning label and retail posting requirements significantly. All cannabis flower labels and cannabinoid product labels must carry six specific verbatim warnings covering child poisoning risk, brain development under age 25, psychosis and schizophrenia risk, dependence and addiction, pregnancy and breastfeeding, and impaired driving. Cannabis retailers must post at least four verbatim warning statements at each retail location covering smoke toxicity, psychotic symptoms, delayed edible onset, and potency-related risks. These are mandated verbatim statements — not general requirements. Operators should audit labels and retail locations against the specific statutory text.

D. Qualified Applicant Status: A Hard Deadline

Qualified applicant status — a general licensing term applicable to any applicant, distinct from the “social equity qualified petitioner” designation used in the reclassification provisions — is the status conferred on an applicant whose application survives initial review without denial. It functions as a conditional approval that holds the applicant’s place in the licensing queue. It normally expires after six months. The Omnibus adds a transitional provision: for any applicant who achieved qualified applicant status before June 1, 2026, that status expires January 1, 2027 — not on the normal six-month clock.

The deadline is hard. OCM must deny any application submitted by an applicant whose status has expired. There is no waiver, no reinstatement, and no OCM discretion. An applicant whose status has expired must reapply from the beginning — new fees, back to the queue. OCM also retains authority to revoke qualified applicant status before expiration if it determines an applicant is not eligible. January 1, 2027 is the outer limit, not a guarantee.

Practitioners should identify any client with qualified applicant status achieved before June 1, 2026, and confirm the path to final authorization is on track.

A related change makes the first preliminary license approval extension mandatory. OCM must grant a onetime extension of up to six months upon request. A second extension of up to six months remains discretionary if the applicant has made good faith efforts. Practitioners should advise clients with preliminary approvals approaching expiration to request the initial extension promptly — OCM cannot decline it.

Part IV: Market-Wide Provisions

A. True Parties of Interest and Shared Premises

True Party of Interest: The Vertical Integration Context

Most cannabis regulatory frameworks restrict how much of the supply chain a single person or entity can control — preventing the same operator from growing, processing, and retailing cannabis. Minnesota is no exception.

The Omnibus clarifies which license types are exempt from that restriction. Microbusinesses, mezzobusinesses, and macrobusinesses are designed to be vertically integrated — their licenses already authorize multiple supply chain activities. The vertical integration prohibition does not apply to them. On the hemp side, an operator may hold LPHE manufacturer, wholesaler, and retailer licenses simultaneously without triggering the prohibition — hemp licenses stack freely with other hemp licenses.

The true party of interest rules follow the same logic. Minnesota requires full disclosure of everyone with an ownership or financial stake in a licensed cannabis or hemp business — and limits how many licenses a single person may have an interest in. Those limits mirror the vertical integration exemptions: where the underlying licenses are permitted to be stacked, the ownership concentration rules are relaxed accordingly.

What this does not change: an individual may not use ownership structures to achieve indirectly what the law prohibits directly. The TPI framework looks through formal business structures to the actual people in control — and holds them to the same limits as the license holder itself.

The Municipal Store Carveout

Minnesota law allows cities and counties to operate their own cannabis retail stores — a model that gives local governments a direct role in the market rather than simply regulating it from the sidelines. An individual who contracts with a city or county to operate up to ten municipal cannabis stores is exempt from the standard ownership concentration rules that apply to other operators. The Omnibus preserves that exemption. Local governments exploring the municipal store model have a continued statutory basis to proceed — and the operator they contract with does not face the same TPI restrictions as a privately licensed retailer.

Shared Premises: A New Operational Pathway

The shared premises provision — the mechanism that enables an individual with majority ownership in both a hemp-licensed business and a cannabis-licensed business to operate both from the same location — is addressed in Part II in the context of hemp licensing. It applies equally to any cannabis or hemp business combination under common majority ownership. All sales and transport of regulated products must be recorded in the statewide monitoring system. Businesses sharing premises are jointly liable for any violations of chapter 342. Practitioners advising operators considering this model should ensure that co-location agreements specifically address joint liability exposure — including indemnification provisions and whether existing insurance policies cover violations by a co-located business. A violation by one business on the shared premises exposes both to enforcement action, license suspension, and civil penalties.

B. Local Control: Evidence Required, Clock Enforced

Three changes to local government authority over cannabis licensing that practitioners advising both operators and municipalities need to understand.

The evidence requirement. Under prior law, a local unit of government could block a license by informing OCM that a proposed cannabis business did not comply with local zoning and land use laws — assertion was sufficient.

That changes with the Omnibus. The local government is now required to submit evidence of noncompliance. OCM must not issue a license if the local government informs OCM of noncompliance and submits evidence of the proposed cannabis business’s lack of compliance. An unsupported assertion no longer blocks the license. This change is a direct legislative response to litigation in which cannabis operators have sued local governments for blocking operations in conflict with the state’s preemption of local prohibition authority.

What this is not. Local zoning remains valid and enforceable. The bill expressly preserves the zoning floor: the proposed cannabis business’s location must meet the requirements of chapter 342 regardless of whether OCM has waived local government certification. What changed is the procedural burden — local governments must now demonstrate noncompliance, not simply assert it. Whether OCM has authority to evaluate the adequacy of submitted evidence and proceed despite an objection it finds insufficient is not resolved in the bill text and may require administrative or judicial resolution.

The 30-day clock. If a local unit of government fails to provide certification within 30 days of receiving a copy of an application from OCM, OCM may waive the certification requirement and issue the license. The waiver is discretionary — OCM may proceed, not must.

Compliance check accountability. Local governments with retail registration authority that perform compliance checks must annually submit data to OCM including the name, address, license number, and business type of each checked business; compliance results; date and time of each check; description of specific violations; and enforcement actions taken. This creates a state-level record of local enforcement activity that OCM did not previously hold.

The proximity buffer. Local governments may prohibit operation within 1,000 feet of a school, or 500 feet of a day care, residential treatment facility, or an attraction within a public park regularly used by minors including a playground or athletic field.

C. Beyond the Headlines

Data Privacy

Seed-to-sale tracking data is now nonpublic. The Omnibus adds statewide monitoring system data to the list of nonpublic data, effective the day following final enactment. Inventory, batch, and compliance data flowing through OCM’s monitoring system is not subject to public data requests — a meaningful protection for operators whose production and compliance records would otherwise be accessible under Minnesota’s data practices laws. One carveout: test results maintained by any cannabis or hemp business remain available for public review. Product safety transparency is preserved even where operational data is not.

Financial Relationships

The Omnibus amends the financial relationship prohibition governing arrangements that could influence product placement, shelf space, or retail positioning between cannabis and hemp businesses. Two new carveouts: the prohibition does not apply to the lawful sale of cannabis plants, cannabis flower, cannabis products, artificially derived cannabinoids, lower-potency hemp edibles, and hemp-derived consumer products in the ordinary course of business; and it does not apply to any transaction entered into in good faith for the sale of goods or services at fair market value.

Psilocybin

OCM must publish a report by January 15, 2027, with recommendations on administering a psilocybin therapeutic use program for individuals 21 and older with qualifying medical conditions. The report must assess program feasibility, describe the viability of a qualifying conditions framework, and include recommendations for program development and administration. This is a report-with-recommendations obligation — not program authorization — but it signals clear legislative direction toward a supervised therapeutic use framework.

The Data Gap

The Omnibus expands the hemp market in Minnesota — new licensing pathways, new container formats, integration with the cannabis supply chain. It does not require OCM to measure any of it.

Chapter 342 mandates an annual cannabis market analysis — tracking license counts, supply adequacy, market stability, and the impact of unregulated sales. That mandate covers cannabis. Hemp, despite being governed by the same chapter and expanded by the same bill, remains outside its scope. The legislature built a more sophisticated hemp market and still did not require anyone to count it.

This gap matters at the state level for precisely the reason it matters at the federal level. The debate over the federal hemp threshold provision is, in significant part, a data argument. Hemp industry proponents can cite a $28.8 billion market and 328,000 jobs because someone counted — at the national level, using national survey data and industry estimates. Minnesota cannot make that argument with its own numbers because it has chosen not to collect them. When the next federal pressure arrives — and given the trajectory of federal hemp policy, it will — Minnesota will be arguing from national estimates rather than its own market record.

Minnesota was a leader in hemp regulation because it moved first and built carefully. The legislature has now built a significantly more sophisticated framework. Requiring OCM to measure what has been built is the next step — and it is one that a future omnibus bill should take.

Conclusion

The 2026 Cannabis Omnibus is not a neutral bill. It is a market architecture document — and it is worth reading it as one.

The two existing medical cannabis operators receive what the industry has sought for years: full vertical integration, a protected market position until at least 2030, and the elimination of the production ratio that constrained their business models. They enter 2027 as the only fully vertically integrated cannabis businesses in the state, with a structural advantage that no new entrant can match before the end of the decade. Whether that outcome reflects sound policy — ensuring supply continuity and medical market stability — or the consolidation of market power in too few hands is a question Minnesota will be living with for the next several years.

For the broader cannabis market, the Omnibus delivers operational clarity: a formalized endorsement system, new product categories, and extended licensing caps that define the competitive landscape through mid-2027. These are meaningful improvements. They are not transformative.

For hemp, the picture is more complicated. The Omnibus restores what prior sessions took away, opens a hospitality pathway that the industry has long needed, and creates a new co-location pathway for individuals who hold majority ownership in both hemp and cannabis businesses. The path forward exists. It is expensive, it is contingent on OCM’s licensing calendar, and it runs through a regulatory framework that has already cost the hemp industry hundreds of businesses. The bones are real. So is the cost of reaching them.

What the 2026 Cannabis Omnibus builds is a layered market — structured, staged, and deliberately concentrated at the top. Whether that structure serves Minnesota’s cannabis and hemp industries, its medical patients, and its broader public interest is the question that the next omnibus will have to answer.

Statutory References

All references are to the enrolled First Unofficial Engrossment of SF 4401 (2026). The Revisor of Statutes has not yet published updated Minnesota Statutes to reflect this legislation. Practitioners should verify all citations against the enrolled bill text.

Part I — Medical Cannabis

1. Cannabis Macrobusiness License — SF 4401, Sec. 103, amending Minn. Stat. § 342.515 (to be renumbered § 342.295 per Sec. 117). Effective January 1, 2027.

2. Macrobusiness License Cap (eight licenses before 2030) — SF 4401, Sec. 103, § 342.515, subd. 9(b). Effective January 1, 2027.

3. Macrobusiness Indoor Canopy Limit (38,000 sq ft) — SF 4401, Sec. 103, § 342.515, subd. 7. Effective January 1, 2027.

4. Macrobusiness Canopy Growth Schedule — SF 4401, Sec. 103, § 342.515, subd. 10. Effective January 1, 2027.

5. Elimination of Medical-to-Adult-Use Production Ratio — SF 4401, Sec. 103, striking prior ratio requirements in § 342.515. Effective January 1, 2027.

6. Macrobusiness LPHE Purchase Authority (immediate) — SF 4401, Sec. 103, § 342.515, subd. 1(a)(6). Effective day following final enactment.

7. Reclassification Pathway (Micro to Mezzo, Mezzo to Macro) — SF 4401, Sec. 14, amending Minn. Stat. § 342.12, subds. 2, 5, and 6. Effective January 1, 2027.

8. Social Equity Floor for Reclassification — SF 4401, Sec. 14, § 342.12, subds. 2(a) and (b). Effective January 1, 2027.

9. Medical Cannabis Endorsement Types (umbrella) — SF 4401, Sec. 96, adding Minn. Stat. § 342.51, subd. 1a. Effective January 1, 2027.

10. Medical Cannabis Cultivation Endorsement — SF 4401, Sec. 96, adding Minn. Stat. § 342.51, subd. 1b. Effective January 1, 2027.

11. Medical Cannabis Manufacturer Endorsement — SF 4401, Sec. 97, adding Minn. Stat. § 342.51, subd. 1c. Effective January 1, 2027.

12. Medical Cannabis Retail Endorsement — SF 4401, Sec. 98, adding Minn. Stat. § 342.51, subd. 1d. Effective January 1, 2027.

13. Distribution Requirements — SF 4401, Sec. 100, amending Minn. Stat. § 342.51, subd. 2. Effective January 1, 2027 (except para. (c), effective day following final enactment).

14. Final Approval for Distribution; Macrobusiness Employment Mandate — SF 4401, Sec. 101, amending Minn. Stat. § 342.51, subd. 3. Effective January 1, 2027.

15. Vaporized Products Prohibition (patients under 21) — SF 4401, Sec. 100, adding Minn. Stat. § 342.51, subd. 2(c). Effective day following final enactment.

16. Repeal of Prior Medical Cannabis Endorsement Framework — SF 4401, Sec. 118(b), repealing Minn. Stat. § 342.51, subd. 1. Effective January 1, 2027.

Part II — Hemp

17. Repeal of Section 151.72 — SF 4401, Sec. 118(a), repealing operative provisions of Minn. Stat. § 151.72. Effective day following final enactment.

18. Common Ownership / Shared Premises — SF 4401, Sec. 38, adding Minn. Stat. § 342.23, subd. 7. Effective day following final enactment.

19. LPHE Combined NPC Ceiling (definition amendment) — SF 4401, Sec. 4, amending Minn. Stat. § 342.01, subd. 50(b)(1)(i). Effective August 1, 2026.

20. Large-Format Hemp Beverage Container — SF 4401, Sec. 107, adding Minn. Stat. § 342.62, subd. 2(i). Effective August 1, 2026.

21. On-Site Consumption Without Alcohol License — SF 4401, Sec. 94, amending Minn. Stat. § 342.46, subd. 8. Effective day following final enactment.

22. LPHE Labeling: Scannable Barcode and THC Symbol Exemption — SF 4401, Sec. 113, adding Minn. Stat. § 342.63, subd. 7. Effective August 1, 2026.

23. LPHE Solid Non-Beverage Package Limits (1,000mg per NPC) — Minn. Stat. § 342.62, subd. 2(f), carried forward in SF 4401, Sec. 107.

Part III — Adult-Use Cannabis

24. Ratio Hemp-Infused Cannabis Product — SF 4401, Sec. 7, adding Minn. Stat. § 342.01, subd. 63a. Effective January 1, 2027.

25. Cannabis Flower Prepackaging and Packaging Endorsement — SF 4401, Sec. 107, amending Minn. Stat. § 342.62, subd. 2. Effective August 1, 2026.

26. Testing Facility Transport (temporary) — SF 4401, Sec. 89, adding Minn. Stat. § 342.425. Effective day following final enactment; expires February 1, 2029.

27. License Cap Dates Extended to July 1, 2027 — SF 4401, Sec. 16, amending Minn. Stat. § 342.14, subd. 1b.

28. Mandatory Warning Language — SF 4401, amending Minn. Stat. §§ 342.63, subds. 2 and 3, and 342.27, subd. 6. Effective August 1, 2026.

29. Qualified Applicant Status Transitional Provision — SF 4401, Sec. 17, amending Minn. Stat. § 342.14, subd. 3. Effective August 1, 2026.

30. Preliminary License Approval Extension (mandatory first extension) — SF 4401, Sec. 19, amending Minn. Stat. § 342.14, subd. 10.

Part IV — Market-Wide Provisions

31. Vertical Integration Prohibition and Exemptions — SF 4401, Sec. 24, amending Minn. Stat. § 342.18, subd. 2. Effective January 1, 2027.

32. True Party of Interest: Application and License Limitations — SF 4401, Secs. 25, 26, and 27, amending Minn. Stat. § 342.185, subds. 1, 2, and 3.

33. Municipal Store Carveout — Minn. Stat. § 342.32, subd. 5 (preserved; not amended by SF 4401).

34. Local Control: Evidence Requirement and 30-Day Clock — SF 4401, Secs. 15 and 33, amending Minn. Stat. § 342.13.

35. Statewide Monitoring System Data — Nonpublic Classification — SF 4401, Sec. 29, amending Minn. Stat. § 342.20. Effective day following final enactment.

36. Financial Relationship Prohibition: New Carveouts — SF 4401, Sec. 37, amending Minn. Stat. § 342.23, subd. 5. Effective day following final enactment.

37. Psilocybin Report — SF 4401, Sec. 116. Report due January 15, 2027.

38. Annual Cannabis Market Analysis (hemp excluded from scope) — Minn. Stat. § 342.04, subd. 2, as amended by SF 4401.

Susan Burns, JD, LL.M., is the founder of S Burns Legal PLLC and a hemp and cannabis regulatory attorney licensed in Minnesota. She is recognized among the Top 200 Cannabis Lawyers Globally and serves on the Council of the MSBA Section of Rural and Agricultural Law. She is founder of the ABA Section of International Law Food, Agriculture, and Cannabis Committee and Special Advisor to the Cannabis Trades Association (UK). She may be reached at susan@sburnslegal.com.